

Supplemental Table 1. Therapeutic interventions, previously described to interfere with haemostasis, identified in the case population and the associated tumor.

Concurrent treatment at time of biopsy or death	Tumor
Aspirin (0.5mg/kg, PO, q24h)	Follicular thyroid adenocarcinoma
Whole blood transfusion (no details)	Splenic haemangiosarcoma
Meloxicam (0.1mg/kg, PO, q24h)	Fibroblastic osteosarcoma with secondary septic osteomyelitis
Meloxicam (0.1mg/kg, PO, q24h)	Ano-rectal adenocarcinoma
Carprofen (4.4mg/kg, SC, q24h)	Low grade mast cell tumor*
Carprofen (2.6mg/kg, PO, q12h)	Soft tissue sarcoma
Meloxicam (0.1mg/kg, PO, q24h)	Bladder transitional cell carcinoma
Vit K ₁ (2.5mg/kg, PO, q12h) Plasma transfusion	Anaplastic haemangiosarcoma of inguinal/mammary region*
Vit K ₁ (dose unknown)	Undifferentiated nasal carcinoma
Whole blood transfusion (43ml/kg) Voluven (10ml/kg bolus)	Hepatic haemangiosarcoma

*Cases with a therapeutic intervention previously described to interfere with haemostasis and distant microthrombi.